



LUND UNIVERSITY

Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy.

Agardh, Elisabet; Lundstig, Annika; Perfilyev, Alexander; Volkov, Petr; Freiburghaus, Tove; Lindholm, Eero; Rönn, Tina; Agardh, Carl-David; Ling, Charlotte

Published in:
BMC Medicine

DOI:
[10.1186/s12916-015-0421-5](https://doi.org/10.1186/s12916-015-0421-5)

2015

[Link to publication](#)

Citation for published version (APA):

Agardh, E., Lundstig, A., Perfilyev, A., Volkov, P., Freiburghaus, T., Lindholm, E., Rönn, T., Agardh, C.-D., & Ling, C. (2015). Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy. *BMC Medicine*, 13(182).
<https://doi.org/10.1186/s12916-015-0421-5>

Total number of authors:
9

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

RESEARCH ARTICLE

Open Access



Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy

Elisabet Agardh¹, Annika Lundstig², Alexander Perfilyev², Petr Volkov², Tove Freiburghaus², Eero Lindholm³, Tina Rönn², Carl-David Agardh³ and Charlotte Ling^{2*}

Abstract

Background: Epigenetic variation has been linked to several human diseases. Proliferative diabetic retinopathy (PDR) is a major cause of vision loss in subjects with diabetes. However, studies examining the association between PDR and the genome-wide DNA methylation pattern are lacking. Our aim was to identify epigenetic modifications that associate with and predict PDR in subjects with type 1 diabetes (T1D).

Methods: DNA methylation was analyzed genome-wide in 485,577 sites in blood from cases with PDR ($n = 28$), controls ($n = 30$), and in a prospective cohort ($n = 7$). False discovery rate analysis was used to correct the data for multiple testing. Study participants with T1D diagnosed before 30 years of age and insulin treatment within 1 year from diagnosis were selected based on 1) subjects classified as having PDR (cases) and 2) subjects with T1D who had had diabetes for at least 10 years when blood DNA was sampled and classified as having no/mild diabetic retinopathy also after an 8.7-year follow-up (controls). DNA methylation was also analyzed in a prospective cohort including seven subjects with T1D who had no/mild diabetic retinopathy when blood samples were taken, but who developed PDR within 6.3 years (converters). The retinopathy level was classified by fundus photography.

Results: We identified differential DNA methylation of 349 CpG sites representing 233 unique genes including *TNF*, *CH13L1* (also known as *YKL-40*), *CHN2*, *GIPR*, *GLRA1*, *GPX1*, *AHRR*, and *BCOR* in cases with PDR compared with controls. The majority of these sites (79 %) showed decreased DNA methylation in cases with PDR. The Natural Killer cell-mediated cytotoxicity pathway was found to be significantly ($P = 0.006$) enriched among differentially methylated genes in cases with PDR. We also identified differential DNA methylation of 28 CpG sites representing 17 genes (e.g. *AHRR*, *GIPR*, *GLRA1*, and *BCOR*) with $P < 0.05$ in the prospective cohort, which is more than expected by chance ($P = 0.0096$).

Conclusions: Subjects with T1D and PDR exhibit altered DNA methylation patterns in blood. Some of these epigenetic changes may predict the development of PDR, suggesting that DNA methylation may be used as a prospective marker of PDR.

Keywords: Diabetic complication, DNA methylation, Epigenetics, Inflammation, Prediction, Proliferative retinopathy, Prospective, Type 1 diabetes

* Correspondence: charlotte.ling@med.lu.se

²Department of Clinical Sciences, Epigenetics and Diabetes Unit, Lund University Diabetes Centre, CRC, Scania University Hospital, 205 02 Malmö, Sweden

Full list of author information is available at the end of the article



© 2015 Agardh et al. **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Proliferative diabetic retinopathy (PDR) and macular edema are the main causes of vision loss in subjects with diabetes [1]. Subjects with type 1 diabetes (T1D) have a higher prevalence of PDR than those with type 2 diabetes (T2D) and key risk factors for development of PDR include hyperglycemia, diabetes duration, hypertension, and genetic factors [1]. The Diabetes Control and Complications Trial has shown that intensive glycemic control reduces the incidence of PDR in subjects with T1D [2]. However, after said trial, the Epidemiology of Diabetes Interventions and Complications research group continued to follow the same subjects and found that the measure of glycemic control, HbA1c, deteriorated in the previously intensively treated group of subjects, while it improved in the conventionally treated one, so that the subsequent HbA1c levels no longer differed during the 10-year follow-up period [3]. Yet the disparity in the cumulative incidence of further progression of PDR between the groups continued to increase, indicating that mechanisms underlying the progressive alterations in retinal microvessels might be long lasting [3]. It has been hypothesized that transient peaks of hyperglycemia might be an independent risk factor for progression of retinopathy in these subjects and that hyperglycemic peaks may cause persistent epigenetic changes despite subsequent normoglycemia [4]. Epigenetic modifications, such as DNA methylation and histone modifications, influence many cellular processes including regulation of gene transcription, embryonic development, X chromosome inactivation, and genomic imprinting [5]. Altered epigenetic patterns may contribute to disease development and differential DNA methylation has been found in subjects with T1D and T2D compared with non-diabetic controls [6–10]. Epigenetic modifications may also influence the development of vascular complications in diabetic subjects and a recent study demonstrated that differential DNA methylation was associated with diabetic nephropathy [11]. However, whether epigenetic modifications are associated with PDR in subjects with T1D remains unknown. The aim of this study was therefore to analyze the genome-wide DNA methylation pattern in blood from subjects with T1D, including 28 cases with PDR and 30 controls. Using a prospective cohort, we also tested if changes in DNA methylation can be found in subjects with T1D prior to development of PDR and thereby predict the disease.

Methods

Study participants

Study participants with T1D, diagnosed before 30 years of age and insulin treatment within 1 year from diagnosis, were selected from the regional diabetes register (Diabetes 2000) according to the following criteria: 1) subjects with T1D for at least 10 years and classified as

having no/mild diabetic retinopathy with, at most, a few microaneurysms at initiation of the study ($n = 37$), and 2) subjects with new-formed pathological retinal vessels classified as having PDR ($n = 28$). All included subjects had genomic DNA isolated from blood cells available. The degree of retinopathy was verified by available fundus photographs (EA) or by record information on vitreous hemorrhage at the time of blood sampling. The degree of retinopathy was thereafter established approximately once per year by fundus photography. After an approximately 6.3-year follow-up, seven out of 37 subjects had developed PDR, forming a prospective follow-up cohort, and were classified as converters. Additionally, after an approximately 8.7-year follow-up, 30 out of 37 subjects were still without PDR and classified as controls; the 28 subjects with PDR were classified as cases. The characteristics of cases and controls are described in Table 1 and of converters and controls in Additional file 1: Table S1. The study was approved by the Regional Ethical Committee (Lund University) and conducted in accordance with the principles of the Helsinki Declaration. All study participants gave written informed consent.

Genome-wide analysis of DNA methylation

The genome-wide DNA methylation analysis was performed using the Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA), which contains 485,577 probes that cover 21,231 (99 %) RefSeq genes [12]. Genomic DNA (500 ng) from blood was bisulfite treated using the EZ DNA methylation kit (Zymo Research, Orange, CA, USA) and subsequently used for analysis of DNA methylation following the Infinium HD Assay Methylation Protocol (Illumina). The BeadChips' images were captured using the Illumina iScan. All included samples showed a high quality bisulfite conversion efficiency (intensity signal >4000) and passed all GenomeStudio quality control steps based on built-in control probes for staining, hybridization, extension, and specificity. In total, 2,309 individual probes were filtered away based on mean detection $P > 0.01$ and 85

Table 1 Characteristics of cases with proliferative diabetic retinopathy and controls included in the genome-wide analysis of DNA methylation in blood from subjects with type 1 diabetes

Characteristics	Controls	Cases	<i>P</i> value
N (male/female)	30 (15/15)	28 (17/11)	
Age (years)*	36.1 \pm 13.7	34.0 \pm 8.5	1
Diabetes duration (years)	17.1 \pm 9.6	21.0 \pm 3.8	1×10^{-4}
HbA1c (%)	7.1 \pm 1.2	8.6 \pm 1.6	2×10^{-4}
Systolic blood pressure (mmHg)	126.7 \pm 15.9	133.0 \pm 21.4	0.44
Diastolic blood pressure (mmHg)	72.9 \pm 9.9	77.0 \pm 8.1	0.15

Data are presented as mean \pm SD. *P* value based on Mann-Whitney two independent samples test. *Age at DNA sampling and fundus photography

Y chromosome probes were filtered away. The raw methylation data was exported from GenomeStudio and analyzed using Bioconductor and the lumi package. Here, β -values were converted to M-values ($M = \log^2(\beta/(1-\beta))$) [13]. Next, data was background corrected by subtracting the median M-value of built in control probes and normalized using quantile normalization [13]. The DNA methylation array data were further corrected for batch effects using COMBAT [13]. Finally, to more easily interpret the results, M-values were reconverted to β -values, which is used when describing the data and creating the figures. All identified significant CpG sites with differences in DNA methylation between PDR cases and controls were screened for cross-reactive probes in the Illumina Infinium HumanMethylation450k BeadChip [14].

Statistical analyses

We performed a principle component analysis of the genome-wide DNA methylation data and correlated the top five principle components with PDR, gender, age, duration of diabetes, and HbA1c. To identify differences in DNA methylation between cases with PDR and controls, a logistic regression model was used, including gender, age, and duration of diabetes as covariates and DNA methylation as a quantitative variable. A false discovery rate (FDR) analysis was used to correct for multiple testing and a FDR less than 5 % ($q < 0.05$) was considered significant. Significant CpG sites were analyzed in the prospective cohort using the same statistical model and covariates, and presented if $P < 0.05$.

Results

Differential DNA methylation of specific CpG sites in cases with PDR

To study the epigenetic basis of PDR in subjects with T1D, DNA methylation of 480,079 CpG sites was analyzed in blood from 28 cases with PDR and 30 controls using the Infinium HumanMethylation450 BeadChip. The characteristics of the cases and controls included in the genome-wide analysis of DNA methylation are described in Table 1. Age was similar between the groups but cases with PDR had longer diabetes duration and higher HbA1c levels than controls (Table 1). To examine the impact of these factors on DNA methylation, we performed a principle component analysis of the genome-wide DNA methylation data and correlated the top five principle components with PDR, gender, age, duration of diabetes, and HbA1c levels. While PDR, gender, age, and duration of diabetes showed significant correlations with one or several of the top five principle components ($P < 0.05$; Additional file 2: Table S2); HbA1c was not significant in this analysis. Based on this result, we included

gender, age, and duration of diabetes as covariates in the regression model where the association between PDR and DNA methylation was studied. After correcting for multiple testing using a FDR analysis, we identified 349 CpG sites representing 233 unique genes that were differentially methylated between cases with PDR and controls ($q < 0.05$; Additional file 3: Table S3). We found decreased DNA methylation in 276 sites (79 %) and increased DNA methylation in 73 sites (21 %) in PDR cases. The absolute differences in DNA methylation ranged from 0.08 % to 13.5 %, representing a fold change of 0.549 to 1.231 and a 45.1 % decrease to a 23.1 % increase in methylation in PDR cases compared with controls (Fig. 1a,b and Additional file 3: Table S3). Based on a literature search, genes with known functions in retina and eye development (*BCOR*, *GFI1*, *GLRA1*, *HDAC4*, *HMGAI1*, *HTT*, *KLF5*, *LAMA4*, and *SHANK1*) [15], inflammation (*AHRR*, *CCL1*, *CD247*, *CD58*, *CD9*, *CXCR5*, *KDM1A*, and *SLC9A3R1*) [16], diabetic complications (*ACTN4*, *ARG1*, *CHI3L1*, *CHN2*, *CNP*, *GIPR*, *GPX1*, *KIFC1*, *NFE2*, *PEMT*, *RPS6KA2*, *TNF*, *TNFAIP3*, and *TNFAIP8*) [17], and oxidative stress (*AHRR*, *BACH2*, *GPX1*, *OXSRI*, *PFKFB3*, and *RCAN1*) [18] were among the genes that showed differential DNA methylation in blood from T1D subjects with PDR (Fig. 1c–f). Some of these genes are represented in several of the analyzed groups.

We then performed a pathway analysis of the 233 genes with one or more CpG sites differentially methylated between cases with PDR and controls using WebGestalt [19]. We found the KEGG pathway “Natural Killer cell mediated cytotoxicity” to be significantly enriched in the PDR cases (adjusted $P = 0.006$), including eight genes: *KLRD1*, *TNF*, *CD247*, *PIK3CD*, *GZMB*, *NFATC1*, *PRF1*, and *KIR2DL4* (Table 2).

Global DNA methylation in blood from cases with PDR and controls

To evaluate the global methylome in blood from cases with PDR and controls, we calculated the average level of DNA methylation in the two groups based on either the functional genome distribution (Fig. 1g) or the CpG content and neighborhood context (Fig. 1h). The results showed no significant differences in global DNA methylation between PDR cases and controls after FDR correction (Fig. 1g,h, Additional file 4: Table S4). Nevertheless, the average level of DNA methylation was high within the gene body, 3'UTR, and in intergenic regions (60–75 %), whereas it was lower in TSS1500 and 5'UTR (23–29 %) and lowest within TSS200 and the first exon (12–14 %; Fig. 1g). In relation to CpG islands, the average methylation was low within the CpG island (15 %), intermediate in the shore regions (43–44 %), and high in the shelf regions and open sea (73–77 %; Fig. 1h).




Fig. 1 (See legend on next page.)

(See figure on previous page.)

Fig. 1 Number of CpG sites with significantly higher (a) or lower (b) DNA methylation in cases with PDR versus controls. Genes involved in retina and eye development (c), inflammation (d), diabetic complications (e), and oxidative stress (f) were among the ones with one or more CpG sites differentially methylated between cases with PDR and controls ($q < 0.05$); data are presented as mean \pm SD. Global DNA methylation is calculated as average DNA methylation based on all CpG sites in each region on the chip and shows no differences between cases with PDR compared with controls in mean methylation value based on gene regions (g) or regions in relation to nearest CpG island (h)

DNA methylation as a prospective marker of PDR

We next tested if differences in DNA methylation may be used as prospective markers of PDR in subjects with T1D. Here, we used DNA from blood from T1D subjects with no/mild diabetic retinopathy when the blood samples were taken, but who developed PDR within approximately 6 years (converters), and compared the degree of DNA methylation in these converters with methylation in control subjects who did not develop PDR (controls; Additional file 1: Table S1). In this prospective cohort there was no significant differences in diabetes duration between converters and controls, but the converters had significantly lower age and higher HbA1c levels ($P < 0.05$; Additional file 1: Table S1) compared to the controls. We examined if any of the 349 CpG sites showing differential DNA methylation in the PDR cases versus controls (Additional file 3: Table S3) also show differential DNA methylation in the prospective cohort. We found 28 sites representing 17 unique genes including *BCOR*, *GIPR*, and *GLRA1* that showed differential DNA methylation in the same direction in the prospective cohort as well as in the case–control cohort with $P \leq 0.05$ (Table 3). This is more than expected by chance based on a χ^2 test ($P = 0.0096$). However, the FDR analysis shows that these sites are only nominally significant in the prospective cohort (Table 3). The majority of these CpG sites

(93 %) exhibit lower methylation in the converters compared with the controls.

Cross-reactive probes

As a quality control, we further screened the 349 sites with significant differences in DNA methylation between PDR cases and controls for cross-reactive probes in the Illumina Infinium HumanMethylation450k BeadChip [14]. Only one of the 349 probes had a perfect match elsewhere in the genome and 13 probes matched for 47–49 out of 50 bases (Additional file 5: Table S5).

Association between HbA1c levels and DNA methylation in blood

We finally tested if HbA1c was associated with differential DNA methylation of individual CpG sites in the control cohort including subjects with T1D without PDR. Gender, age, and diabetes duration were included as covariates in the linear regression model. However, after correction for multiple testing using FDR, no significant association between HbA1c and DNA methylation was found ($q = 0.99$). Additionally, HbA1c was only associated with methylation of 14,522 CpG sites at $P < 0.05$, which is much less than expected by chance.

Even though HbA1c was not significantly associated with DNA methylation based on this linear regression analysis, nor based on the principle component analysis, we tested to include HbA1c in the regression model for the association between DNA methylation and PDR, as there was a significant difference in HbA1c between PDR cases and controls. Although not genome-wide significant ($q = 0.08–0.38$), the 349 CpG sites detected to be differentially methylated between PDR cases and controls in our main analysis ($q < 0.05$; Additional file 3: Table S3) all still showed a strong nominal association ($P = 4.0 \times 10^{-7}$ to 7.6×10^{-3}) after inclusion of HbA1c in the model (Additional file 6: Table S6). Thereby, our results support that adjustment for HbA1c has no major effect on the association between PDR and DNA methylation, but it makes the study less well powered since the size of our study only supports the inclusion of up to four variables in the regression analysis in order to maintain statistical power. Additionally, when including HbA1c in the model we found increased standard errors in the regression analysis of all 349 CpG sites (Additional file 6: Table S6), indeed suggesting that this additional variable makes the model less stable.

Table 2 Pathway analysis of genes with CpG sites differentially methylated in cases with PDR versus controls

KEGG pathway: Natural Killer cell mediated cytotoxicity ($P = 0.0001$; $P_{adj} = 0.0063$)		
Total # of genes in pathway: 121	Expected # of genes: 1.48	Observed # of genes: 8
Gene symbol	Description	
<i>KLRD1</i>	Killer cell lectin-like receptor subfamily D, member 1	
<i>TNF</i>	Tumor necrosis factor	
<i>CD247</i>	CD247 molecule	
<i>PIK3CD</i>	Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta	
<i>GZMB</i>	Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)	
<i>NFATC1</i>	Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1	
<i>PRF1</i>	Perforin 1 (pore forming protein)	
<i>KIR2DL4</i>	Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4	

Table 3 CpG sites showing significant differences in DNA methylation between cases with PDR and controls (FDR $q < 5\%$, Additional file 3: Table S3), that are also nominally differentially methylated in the same direction in the converters of the prospective cohort at $P < 0.05$

Probe ID	Chr	Location in relation to:			DNA Methylation (%)				
		Nearest gene	Gene region	CpG Island	Controls	Converters	Difference	P value	q value
cg26703534	5	AHRR	Body	S Shelf	63.6 ± 2.6	59.9 ± 4.1	-3.7	9.5×10^{-4}	0.17
cg05575921	5	AHRR	Body	N Shore	82.4 ± 6.3	75.0 ± 8.1	-7.4	2.1×10^{-3}	0.18
cg07339236	20	ATP9A	Body	Open sea	18.0 ± 2.5	15.6 ± 1.6	-2.4	0.013	0.35
cg05026884	X	BCOR	5'UTR	Island	26.5 ± 11.1	22.7 ± 4.7	-3.8	4.2×10^{-3}	0.21
cg01490258	X	BCOR	5'UTR	N Shore	13.2 ± 2.9	12.4 ± 2.0	-0.8	0.010	0.33
cg23701759	X	BCOR	5'UTR	Island	34.9 ± 4.9	30.9 ± 3.7	-4.0	0.014	0.35
cg10055320	X	BCOR	5'UTR	N Shore	42.2 ± 4.4	39.2 ± 5.1	-3.0	0.029	0.50
cg00507154	19	C19orf76	1 st Exon; 5'UTR	Island	70.2 ± 4.6	67.7 ± 2.6	-2.5	0.030	0.50
cg08601628	8	C8orf74	Body	Open sea	82.5 ± 3.0	80.6 ± 3.2	-1.9	0.022	0.43
cg12993916	6	DTNBP1	Body	Open sea	78.9 ± 3.0	76.8 ± 3.7	-2.1	0.015	0.35
cg03636183	19	F2RL3	Body	N Shore	68.9 ± 4.4	65.1 ± 4.7	-3.8	9.3×10^{-3}	0.32
cg02942825	19	GIPR	3'UTR	S Shore	49.8 ± 3.2	48.0 ± 5.8	-1.8	0.050	0.62
cg17808910	7	GLCCI1	Body	S Shelf	73.7 ± 3.9	75.5 ± 4.6	1.8	0.048	0.62
cg26567012	5	GLRA1	3'UTR	Open sea	55.4 ± 3.8	52.0 ± 6.0	-3.4	0.030	0.50
cg01010839	10	NET1	TSS1500; Body	N Shore	71.2 ± 4.3	70.2 ± 2.2	-1.0	0.015	0.35
cg24796663	6	PHF1	TSS1500	N Shore	12.9 ± 1.8	11.3 ± 1.9	-1.6	1.5×10^{-3}	0.17
cg11224624	8	PLEC1	Body	Island	2.1 ± 0.3	2.3 ± 0.3	0.2	0.033	0.52
cg22291265	19	SHANK1	Body	Open sea	7.5 ± 2.3	6.9 ± 1.3	-0.6	0.050	0.62
cg06589051	2	TGFBAP1	TSS1500	S Shore	72.4 ± 2.0	70.2 ± 4.1	-2.2	0.040	0.61
cg08597832	8	TOP1MT	Body	N Shore	82.1 ± 2.5	79.8 ± 2.7	-2.3	0.020	0.41
cg11166303	2	TSSC1	Body	N Shore	67.8 ± 7.5	61.2 ± 8.5	-6.6	4.0×10^{-3}	0.21
cg09577317	8		Intergenic	N Shore	83.9 ± 1.6	81.0 ± 1.2	-2.9	1.7×10^{-4}	0.058
cg07948143	14		Intergenic	Open sea	75.5 ± 3.2	71.0 ± 4.6	-4.5	2.9×10^{-3}	0.20
cg24058013	18		Intergenic	Island	89.8 ± 1.0	87.7 ± 1.8	-2.1	5.4×10^{-3}	0.24
cg03889263	3		Intergenic	Open sea	20.0 ± 3.9	15.9 ± 2.6	-4.1	6.9×10^{-3}	0.27
cg05546763	14		Intergenic	Island	82.0 ± 2.0	80.6 ± 2.3	-1.4	0.016	0.36
cg15342087	6		Intergenic	Open sea	81.1 ± 2.1	80.2 ± 2.2	-0.9	0.046	0.62
cg06126421	6		Intergenic	Open sea	69.2 ± 6.2	69.0 ± 4.4	-0.2	0.050	0.62

Data are presented a mean ± SD

Discussion

In the present study, we demonstrate for the first time that differential DNA methylation in/near 233 unique genes is associated with PDR in a case-control cohort. In a prospective cohort, we also found epigenetic markers that can predict PDR. Our study suggests that DNA methylation in blood can be used as a predictive biomarker of PDR in subjects with T1D. However, replication studies are needed to verify our results.

Diabetic retinopathy is a common microvascular complication and, in its severe forms, the leading cause of blindness among working-aged adults in the western world [1]. In PDR, ischemia is preceding formation of new vessels, which untreated can result in vitreous hemorrhage

and retinal detachment. Inflammation does also play a key role in development of microvascular diabetic complications, including PDR [17]. Subjects with T1D have a relatively high prevalence of diabetic retinopathy compared with subjects with T2D and it is well established that HbA1c levels, diabetes duration, and hypertension increase the risk for PDR [20]. Previous studies have tried to identify biomarkers that can be used to clinically predict diabetic retinopathy in subjects with diabetes [21]. However, so far, limited breakthroughs have taken place [22–24]. In our study, we chose to identify markers, not for diabetic retinopathy per se but for the most severe consequence of ischemic retinopathy, i.e. PDR. Since diabetes duration and degree of non-proliferative retinopathy

are risk factors for PDR development, we aimed at including control subjects with as low risk as possible. It was not possible to identify a sufficient number of control subjects with at least 10 years of diabetes who were also completely without microaneurysms, but as occasional microaneurysms may come and go we included subjects with a few microaneurysms. Using a longitudinal approach, we could conclude that 81 % (30 out of 37 subjects) of these subjects still were without PDR approximately 8 years later and they were assigned as controls. Progression to PDR occurred in seven subjects (19 %) and were assigned converters. Those subjects differed from both cases and controls by younger age and poorer metabolic control measured by HbA1c. Those characteristics are associated with a high risk for the rapid development of severe PDR, also known as florid retinopathy [25], which results in severe visual impairment or blindness if not properly treated in time. Based on our study design, we have been able not only to identify epigenetic markers associated with PDR but also predictive of the most severe form of diabetic retinopathy in T1D.

We identified 349 CpG sites representing 233 genes with altered DNA methylation levels in T1D subjects with PDR. The majority of these sites (79 %) showed decreased DNA methylation in cases with PDR. A lower methylation level may be associated with higher expression as DNA methylation has been shown to repress the binding of transcription factors to promoter regions and attract proteins such as transcriptional co-repressors and histone deacetyltransferases associated with a dense chromatin structure and inactive genes [5]. Although it would have been interesting to also study gene expression in the present case-control cohort, this was not possible since only DNA was extracted when blood was collected. Nevertheless, DNA methylation in blood can quite easily be used as a biomarker that predicts disease and the epigenetic alterations found in the present study suggest that this may be possible in subjects with T1D.

Several identified genes with altered DNA methylation in cases with PDR, such as *TNF*, *CHI3L1*, and *CHN2*, encode proteins with previous known function in diabetic complications and/or diabetic retinopathy [17]. *TNF*, which encodes tumor necrosis factor, exhibits decreased DNA methylation in cases with PDR. Tumor necrosis factor is a proinflammatory cytokine that is elevated in serum from subjects with PDR [26]. Epigenetic modifications of *TNF* in T1D subjects may subsequently regulate the expression of *TNF* and thereby contribute to inflammation in diabetic retinopathy. *CHI3L1*, also known as *YKL-40*, encodes an inflammatory glycoprotein involved in endothelial dysfunction and cardiovascular disease [27]. We found decreased DNA methylation of *CHI3L1* in cases with PDR, which may contribute to increased expression of this gene. Interestingly, serum levels of YKL-40 were elevated

in subjects with diabetic retinopathy [28] and ischemia was associated with higher *YKL-40* mRNA levels in carotid plaque [29]. As ischemia precedes PDR, it may also affect methylation and/or expression of *CHI3L1* in subjects with diabetic retinopathy. Cases with PDR also exhibited decreased DNA methylation of *CHN2*, which encodes chimerin 2, a protein known to affect proliferation and migration of smooth muscle cells. Interestingly, a SNP in an intron of *CHN2* was recently associated with diabetic retinopathy in Chinese people with T2D, further supporting a role for this gene in the development of diabetic retinopathy [30].

The largest absolute difference in DNA methylation between PDR cases and controls was 13.5 %, which represents a fold change of 1.22. Our epigenetic data are in line with previous genetic studies where the odds ratio of most genetic variants associated with PDR has been modest [31]. However, we identified more than 200 genes with differential DNA methylation in PDR cases after correction for multiple testing and it is possible that modest changes of multiple genes together contribute to the disease phenotype. The present study is, to our knowledge, the first one to analyze DNA methylation genome-wide in subjects with PDR. However, a previous study by Bell et al. [11] also reported absolute differences in DNA methylation of approximately 10 % when DNA methylation of approximately 27,000 sites was analyzed in blood from subjects with diabetic nephropathy.

In order to assess if epigenetic modifications may be used as biomarkers that predict PDR, we analyzed DNA methylation in a prospective cohort. Differential DNA methylation may predict PDR as several epigenetic modifications identified in cases with PDR were also found in our prospective cohort. *BCOR* encoding BCL6 co-repressor has the most CpG sites differentially methylated in both the case-control cohort and in the prospective cohort. While these data suggest that epigenetic modifications of *BCOR* may be used to predict PDR, larger prospective studies are needed to further validate our findings. *GIPR*, encoding glucose-dependent insulinotropic polypeptide receptor, also showed decreased DNA methylation in our prospective cohort as well as in the cases with PDR, and may subsequently be used as a candidate gene that predicts PDR. Interestingly, a previous study found increased expression of the *GIPR* in the retinas of streptozotocin-induced diabetic rats [32]. However, whether expression of the *GIPR* is increased in the human retina of diabetic subjects remains unknown and will be ethically difficult to analyze. The prospective cohort also confirmed demethylation of the aryl hydrocarbon receptor repressor (*AHRR*) in PDR cases, a locus which has been repeatedly shown to associate with smoking [33–35]. Unfortunately, we do not have access to smoking status in our study from when samples were collected and hence

we cannot rule out that altered smoking habits between the groups may affect this association.

Our study supports a role of epigenetic variation in the pathogenesis of PDR. Furthermore, the heritability of PDR has been estimated to 27 % and genetic variants may thereby affect the risk for PDR [36]. However, although genome-wide association studies have been performed to identify genetic variants associated with PDR, the outcome from these studies was limited [36–38]. It is possible that genetic variants interact with epigenetic variation to increase the risk for disease [39, 40]. However, further genome-wide studies are needed to dissect whether interactions between genetics and epigenetics play a role in PDR.

Conclusion

Together, our study is the first to identify epigenetic modifications in T1D subjects with PDR. Our data suggest that differential DNA methylation may contribute to the pathogenesis of PDR in subjects with T1D and that DNA methylation in blood may be used as a predictive biomarker for this severe type of diabetic retinopathy. However, replication is needed to establish whether the findings really represent a novel biomarker of retinopathy risk.

Additional files

Additional file 1: Table S1. Characteristics of type 1 diabetic subjects converting to proliferative diabetic retinopathy (converters) and controls. (DOC 35 kb)

Additional file 2: Table S2. *P* values for correlations of the top five principle components for the DNA methylation data with proliferative diabetic retinopathy, gender, age, duration of diabetes, and HbA1c levels. (DOC 30 kb)

Additional file 3: Table S3. CpG sites significantly different between type 1 diabetic subjects with (cases) and without (controls) proliferative diabetic retinopathy (false discovery rate <5 %). (DOC 554 kb)

Additional file 4: Table S4. Average level of DNA methylation for regions in relation to nearest gene or CpG islands, in type 1 diabetic subjects with (cases) or without (controls) proliferative diabetic retinopathy. (DOC 42 kb)

Additional file 5: Table S5. The 14 cross-reactive probes with number of bases matched to cross-reactive target(s). (DOC 43 kb)

Additional file 6: Table S6. Associations between proliferative diabetic retinopathy (PDR) and DNA methylation when adding HbA1c to the logistic regression model for all the 349 CpG sites significantly different between type 1 diabetic subjects with (cases) and without (controls) PDR based on a false discovery rate of <5 % in the main analysis. Beta coefficients and standard error of the mean (SE) are presented for the regression analysis both with and without HbA1c in the model. (DOC 631 kb)

Abbreviations

FDR: False discovery rate; PDR: Proliferative diabetic retinopathy; T1D: Type 1 diabetes; T2D: Type 2 diabetes.

Competing interests

The authors declare that there are no conflicts of interest associated with this manuscript.

Authors' contributions

EA, CDA, and CL designed the study and experiments. AP, PV, EL, and TR contributed to the design of the study and the experiments. EA, AL, AP, PV, TF, TR, and CL performed the research and analyzed data. All authors interpreted and discussed the data. EA, AL, and CL wrote the manuscript. All authors reviewed and revised the manuscript critically. All authors approved the final version of the manuscript. EA and CL are the guarantors of this work and, as such, had full access to all of the study data and take responsibility for the integrity of the data.

Acknowledgments

This work was supported by grants from the Swedish Research Council, including Dnr. 521-2010-2745, Dnr. 523-2010-1061, a Linnaeus grant (LUDC: Dnr. 349-2008-6589) and strategic research area grant (EXODIAB: Dnr. 2009-1039), ALF, the Novo Nordisk Foundation, the Swedish Diabetes foundation, the Järnhardt Foundation, the Foundation for Visually Impaired in Former Malmöhus län, the Swedish Medical Society, the Swedish Eye Foundation, the Skåne University Hospital Foundation, and Pahlsson foundation as well as equipment grants from Wallenberg KAW (2009-0243) and Lundberg Foundation (grant no. 359). We thank SCIBLU at Lund University for analyzing global DNA methylation.

Author details

¹Department of Clinical Sciences, Ophthalmology, Lund University, Scania University Hospital, 205 02 Malmö, Sweden. ²Department of Clinical Sciences, Epigenetics and Diabetes Unit, Lund University Diabetes Centre, CRC, Scania University Hospital, 205 02 Malmö, Sweden. ³Department of Clinical Sciences, Endocrinology, Lund University, Scania University Hospital, 205 02 Malmö, Sweden.

Received: 3 November 2014 Accepted: 15 July 2015

Published online: 06 August 2015

References

1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35:556–64.
2. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. *N Engl J Med*. 2000;342:381–9.
3. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol*. 2008;126:1707–15.
4. El-Osta A, Brasacchio D, Yao D, Poci A, Jones PL, Roeder RG, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. *J Exper Med*. 2008;205:2409–17.
5. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. *Diabetes*. 2009;58:2718–25.
6. Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. *Diabetes*. 2008;57:3189–98.
7. Nitert MD, Dayeh T, Volkov P, Elgzyri T, Hall E, Nilsson E, et al. Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. *Diabetes*. 2012;61:3322–32.
8. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. *PLoS Genet*. 2011;7:e1002300.
9. Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA1c levels in human pancreatic islets. *Diabetologia*. 2011;54:360–7.
10. Yang BT, Dayeh TA, Volkov PA, Kirkpatrick CL, Malmgren S, Jing X, et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. *Mol Endocrinol*. 2012;26:1203–12.
11. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. *BMC Med Genet*. 2010;3:33.

12. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA methylation array with single CpG site resolution. *Genomics*. 2011;98:288–95.
13. Rönn T, Volkov P, Davegardh C, Dayeh T, Hall E, Olsson AH, et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. *PLoS Genet*. 2013;9:e1003572.
14. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics*. 2013;8:203–9.
15. Ohuchi H. Molecular aspects of eye evolution and development: from the origin of retinal cells to the future of regenerative medicine. *Acta Med Okayama*. 2013;67:203–12.
16. Nguyen DV, Shaw LC, Grant MB. Inflammation in the pathogenesis of microvascular complications in diabetes. *Front Endocrinol*. 2012;3:170.
17. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev*. 2013;93:137–88.
18. Reis JS, Veloso CA, Mattos RT, Purish S, Nogueira-Machado JA. Oxidative stress: a review on metabolic signaling in type 1 diabetes. *Arquivos Brasileiros Endocrinol Metabol*. 2008;52:1096–105.
19. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GENE SeT Analysis Toolkit (WebGestalt): update 2013. *Nucleic Acids Res*. 2013;41:W77–83.
20. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. *Diabetes Care*. 1992;15:1875–91.
21. Freeman WM, Bixler GV, Brucklacher RM, Lin CM, Patel KM, VanGuilder HD, et al. A multistep validation process of biomarkers for preclinical drug development. *Pharmacogenomics J*. 2010;10:385–95.
22. Blum A, Socea D, Ben-Shushan RS, Keinan-Boker L, Naftali M, Segol G, et al. A decrease in VEGF and inflammatory markers is associated with diabetic proliferative retinopathy. *Eur Cytokine Netw*. 2012;23:158–62.
23. Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. *Diabetes Care*. 2011;34:1081–5.
24. Muni RH, Kohly RP, Lee EQ, Manson JE, Semba RD, Schaumberg DA. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. *JAMA Ophthalmol*. 2013;131:514–21.
25. Agardh E. Rapid, bloody, and blinding diabetic retinopathy. *Acta Ophthalmol (Copenh)*. 2010;88:274–8.
26. Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. *J Diabetes Complicat*. 2008;22:309–16.
27. Rathcke CN, Vestergaard H. YKL-40 – an emerging biomarker in cardiovascular disease and diabetes. *Cardiovasc Diabetol*. 2009;8:61.
28. Sakamoto F, Katakami N, Kaneto H, Yasuda T, Takahara M, Miyashita K, et al. Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus. *Endocr J*. 2013;60:73–9.
29. Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-Sorensen K, et al. Increased YKL-40 expression in patients with carotid atherosclerosis. *Atherosclerosis*. 2010;211:589–95.
30. Hu C, Zhang R, Yu W, Wang J, Wang C, Pang C, et al. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. *Diabetes*. 2011;60:3085–9.
31. Sheu WH, Kuo JZ, Lee IT, Hung YJ, Lee WJ, Tsai HY, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. *Hum Mol Genet*. 2013;22:3165–73.
32. Cho GJ, Ryu S, Kim YH, Kim YS, Cheon EW, Park JM, et al. Upregulation of glucose-dependent insulinotropic polypeptide and its receptor in the retina of streptozotocin-induced diabetic rats. *Curr Eye Res*. 2002;25:381–8.
33. Allione A, Marcon F, Fiorito G, Guarrera S, Siniscalchi E, Zijno A, et al. Novel epigenetic changes unveiled by monozygotic twins discordant for smoking habits. *PLoS One*. 2015;10:e0128265.
34. Monick MM, Beach SR, Plume J, Sears R, Gerrard M, Brody GH, et al. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. *Am J Med Genet B Neuropsychiatr Genet*. 2012;159B:141–51.
35. Richmond RC, Simpkin AJ, Woodward G, Gaunt TR, Lyttleton O, McArdle WL, et al. Prenatal exposure to maternal smoking and offspring DNA methylation across the lifecourse: findings from the Avon Longitudinal Study of Parents and Children (ALSPAC). *Hum Mol Genet*. 2015;24:2201–17.
36. Cho H, Sobrin L. Genetics of diabetic retinopathy. *Current Diabetes Reports*. 2014;14:515.
37. Awata T, Yamashita H, Kurihara S, Morita-Ohkubo T, Miyashita Y, Katayama S, et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. *PLoS One*. 2014;9:e111715.
38. Petrovic D. Candidate genes for proliferative diabetic retinopathy. *Biomed Res Int*. 2013;2013:540416.
39. Dayeh TA, Olsson AH, Volkov P, Almgren P, Rönn T, Ling C. Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets. *Diabetologia*. 2013;56:1036–46.
40. Olsson AH, Volkov P, Bacos K, Dayeh T, Hall E, Nilsson EA, et al. Genome-wide associations between genetic and epigenetic variation influence mRNA expression and insulin secretion in human pancreatic islets. *PLoS Genet*. 2014;10:e1004735.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

